missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human ABHD17A (aa 53-80) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (71%), Rat (71%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-140126 (PA5-140126. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Hydrolyzes fatty acids from S-acylated cysteine residues in proteins (PubMed:26701913). Has depalmitoylating activity towards NRAS (PubMed:26701913). Has depalmitoylating activity towards DLG4/PSD95 (PubMed:26701913). May have depalmitoylating activity towards MAP6. [UniProt]
Specifications
Specifications
| Accession Number | Q96GS6 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 81926 |
| Name | Human ABHD17A (aa 53-80) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1700013O15Rik; Abhd17a; abhydrolase domain containing 17 A; abhydrolase domain containing 17 A, depalmitoylase; abhydrolase domain-containing protein 17 A; abhydrolase domain-containing protein FAM108A; abhydrolase domain-containing protein FAM108A1; alpha/beta hydrolase domain-containing protein 17 A; BC005632; C19orf27; D10Bwg1364e; FAM108A; FAM108A1; family with sequence similarity 108, member A; family with sequence similarity 108, member A1; mFLJ00358 protein; MGC138013 protein; protein ABHD17A; RGD1359682; upf0227 |
| Common Name | ABHD17A |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction